A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

NCT05071313 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

777

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza, Human Prevention
Respiratory Syncytial Viruses Prevention

Interventions

BIOLOGICAL: Ad26.RSV.preF-based vaccine
BIOLOGICAL: Quadrivalent High-dose Influenza Vaccine
BIOLOGICAL: Placebo

Sponsor

Janssen Vaccines & Prevention B.V.